- 208
Chuck Close
Estimate
30,000 - 40,000 USD
bidding is closed
Description
- Chuck Close
- Self-Portrait
- screenprint
- sheet 1374 by 1665 mm 66 1/2 by 55 in
Screenprint in colors, 2012, signed in pencil, dated and inscribed 'ADDF Proof', a proof aside from the edition of 80 (total edition includes 15 artist's proofs), on wove paper, published by Pace Editions, Inc., New York, framed *(not examined out of frame)
Condition
The print is in good condition, with full margins. *(not examined out of frame)
In response to your inquiry, we are pleased to provide you with a general report of the condition of the property described above. Since we are not professional conservators or restorers, we urge you to consult with a restorer or conservator of your choice who will be better able to provide a detailed, professional report. Prospective buyers should inspect each lot to satisfy themselves as to condition and must understand that any statement made by Sotheby's is merely a subjective qualified opinion.
NOTWITHSTANDING THIS REPORT OR ANY DISCUSSIONS CONCERNING CONDITION OF A LOT, ALL LOTS ARE OFFERED AND SOLD "AS IS" IN ACCORDANCE WITH THE CONDITIONS OF SALE PRINTED IN THE CATALOGUE.
In response to your inquiry, we are pleased to provide you with a general report of the condition of the property described above. Since we are not professional conservators or restorers, we urge you to consult with a restorer or conservator of your choice who will be better able to provide a detailed, professional report. Prospective buyers should inspect each lot to satisfy themselves as to condition and must understand that any statement made by Sotheby's is merely a subjective qualified opinion.
NOTWITHSTANDING THIS REPORT OR ANY DISCUSSIONS CONCERNING CONDITION OF A LOT, ALL LOTS ARE OFFERED AND SOLD "AS IS" IN ACCORDANCE WITH THE CONDITIONS OF SALE PRINTED IN THE CATALOGUE.
Catalogue Note
Founded in 1998 by Co-Chairmen Leonard and Ronald Lauder, the ADDF’s mission is to accelerate the discovery of drugs to prevent, treat and cure Alzheimer’s disease, related dementias and cognitive aging. 100% of funds raised by the ADDF is used to support Alzheimer’s drug research and related programs. The ADDF has granted more than $55 million to fund 385 Alzheimer’s drug discovery programs and clinical trials in academic centers and biotechnology companies in 18 countries.